Ravi Rajaram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ravi Rajaram has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Mara B. Antonoff
Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, USA
9 shared publicationsWayne L. Hofstetter
Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, USA
8 shared publicationsDavid C. Rice
Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, USA
7 shared publicationsAra A. Vaporciyan
Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, USA
6 shared publicationsReza J. Mehran
Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, USA
6 shared publicationsStephen G. Swisher
Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, USA
6 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 11482
ASO Visual Abstract: Financial Toxicity in Patients with Resected Esophageal Cancer
- 15 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 11482
Open AccessASO Visual Abstract: Financial Toxicity in Patients with Resected Esophageal Cancer
- Open Access
- 6 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 11472-11479
Financial Toxicity in Patients with Resected Esophageal Cancer
Background: Esophagectomy for esophageal cancer is associated with significant morbidity and can result in financial hardship, yet this aspect of survivorship remains understudied. This study evaluated the prevalence and risk factors of financial toxicity (FT) among patients following esophagectomy. Methods: Patients who underwent esophagectomy between January 2016 and September 2022 were surveyed about demographic, financial, and employment history. Financial toxicity was measured by using the validated COST survey. Multivariate analyses identified predictors of FT. Results: Of 370 patients contacted, 159 (43%) completed the survey. Median age was 65.3 years; 82.4% were male. Following therapy, 44.7% reported decreased work hours or stopped working entirely. Insurance was employer-based for 50.3%, while 40.6% had Medicare. Financial toxicity was reported by 37.1%. Risk factors included larger household size (odds ratio 2.3), low credit score (odds ratio 13.2), while high income and active retirement were protective. Conclusions: More than a third of esophagectomy patients were found to have FT. Those with poor baseline financial health or disrupted employment were most vulnerable and may benefit from early financial counseling and support interventions.
- 6 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 11472-11479
Open AccessFinancial Toxicity in Patients with Resected Esophageal Cancer
Background: Esophagectomy for esophageal cancer is associated with significant morbidity and can result in financial hardship, yet this aspect of survivorship remains understudied. This study evaluated the prevalence and risk factors of financial toxicity (FT) among patients following esophagectomy. Methods: Patients who underwent esophagectomy between January 2016 and September 2022 were surveyed about demographic, financial, and employment history. Financial toxicity was measured by using the validated COST survey. Multivariate analyses identified predictors of FT. Results: Of 370 patients contacted, 159 (43%) completed the survey. Median age was 65.3 years; 82.4% were male. Following therapy, 44.7% reported decreased work hours or stopped working entirely. Insurance was employer-based for 50.3%, while 40.6% had Medicare. Financial toxicity was reported by 37.1%. Risk factors included larger household size (odds ratio 2.3), low credit score (odds ratio 13.2), while high income and active retirement were protective. Conclusions: More than a third of esophagectomy patients were found to have FT. Those with poor baseline financial health or disrupted employment were most vulnerable and may benefit from early financial counseling and support interventions.
- Open Access
Nodal Staging in Patients with Locally Advanced Non-Small Cell Lung Cancer: Indications, Approaches, and Impact on Downstream Treatment Selection
Locally advanced non-small cell lung cancer (NSCLC) is a biologically and clinically heterogeneous disease in which mediastinal lymph node involvement remains the principal prognostic and therapeutic discriminator. Accurate nodal staging guides selection among surgical resection, definitive chemoradiotherapy, immunotherapy, and targeted therapy. This narrative review synthesizes contemporary evidence on mediastinal staging modalities, nodal disease burden, and treatment selection in stage II-III NSCLC. Contemporary staging integrates CT and FDG-PET/CT with systematic tissue confirmation using EBUS-TBNA and EUS, with surgical mediastinal staging reserved for selected high-risk or discordant cases. The ninth edition TNM N2a/N2b distinction, increasing use of neoadjuvant and perioperative immunotherapy, and molecularly guided therapy have further amplified the clinical consequences of under- or over-staging. Nodal assessment should therefore be interpreted through a multidisciplinary framework that integrates anatomy, biology, treatment response, and patient operability.
Open AccessNodal Staging in Patients with Locally Advanced Non-Small Cell Lung Cancer: Indications, Approaches, and Impact on Downstream Treatment Selection
Locally advanced non-small cell lung cancer (NSCLC) is a biologically and clinically heterogeneous disease in which mediastinal lymph node involvement remains the principal prognostic and therapeutic discriminator. Accurate nodal staging guides selection among surgical resection, definitive chemoradiotherapy, immunotherapy, and targeted therapy. This narrative review synthesizes contemporary evidence on mediastinal staging modalities, nodal disease burden, and treatment selection in stage II-III NSCLC. Contemporary staging integrates CT and FDG-PET/CT with systematic tissue confirmation using EBUS-TBNA and EUS, with surgical mediastinal staging reserved for selected high-risk or discordant cases. The ninth edition TNM N2a/N2b distinction, increasing use of neoadjuvant and perioperative immunotherapy, and molecularly guided therapy have further amplified the clinical consequences of under- or over-staging. Nodal assessment should therefore be interpreted through a multidisciplinary framework that integrates anatomy, biology, treatment response, and patient operability.
- Open Access
- 18 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1893
Shape-Sensing Robotic Bronchoscopy with Integrated Mobile Cone-Beam CT Guidance for Intraoperative Localization of Lung Tumors Using Indocyanine Green
Background/Objectives: With increasing frequency in sublobar resections, accurate intraoperative localization has become essential to ensure adequate resection margins and spare lung parenchyma. Our study evaluates the efficacy of shape-sensing robotic bronchoscopy (SS-RAB) with integrated mobile cone-beam CT (mCBCT) for intraoperative localization of lung tumors using indocyanine green (ICG). We further aimed to explore the feasibility of a single intubation-single positioning technique for bronchoscopy and surgery. Methods: We retrospectively reviewed patients who underwent SS-RAB with integrated mCBCT for ICG marking, followed by minimally invasive sublobar resection. ICG marking was deemed successful when it allowed the operative team to localize and resect the lesion with adequate pathology margins. Results: A total of 28 patients with 30 pulmonary lesions from a single institution were included. Median tumor size was 10.5 mm (IQR, 8.7–14.6 mm) and distance from pleura 7.8 mm (IQR, 2.45–13.8 mm). Twenty lesions (66.6%) were solid, 5 lesions (16.6%) semi-solid, and 5 lesions (16.6%) ground-glass. ICG localization was successful in 28 lesions (93%). Nineteen patients (68%) were intubated only with a double-lumen endotracheal tube (DL-ETT), used for bronchoscopy and surgery, and in 10 patients (36%) ICG marking and surgery were both performed in lateral decubitus. One patient developed a small pneumothorax during bronchoscopy which did not prevent ICG injection. Conclusions: SS-RAB with integrated mCBCT for ICG marking is successful and safe. Single intubation with DL-ETT and lateral decubitus positioning for both bronchoscopy and surgery are feasible. Further studies are needed to prove a potential increase in efficiency with this technique.
- 18 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1893
Open AccessShape-Sensing Robotic Bronchoscopy with Integrated Mobile Cone-Beam CT Guidance for Intraoperative Localization of Lung Tumors Using Indocyanine Green
Background/Objectives: With increasing frequency in sublobar resections, accurate intraoperative localization has become essential to ensure adequate resection margins and spare lung parenchyma. Our study evaluates the efficacy of shape-sensing robotic bronchoscopy (SS-RAB) with integrated mobile cone-beam CT (mCBCT) for intraoperative localization of lung tumors using indocyanine green (ICG). We further aimed to explore the feasibility of a single intubation-single positioning technique for bronchoscopy and surgery. Methods: We retrospectively reviewed patients who underwent SS-RAB with integrated mCBCT for ICG marking, followed by minimally invasive sublobar resection. ICG marking was deemed successful when it allowed the operative team to localize and resect the lesion with adequate pathology margins. Results: A total of 28 patients with 30 pulmonary lesions from a single institution were included. Median tumor size was 10.5 mm (IQR, 8.7–14.6 mm) and distance from pleura 7.8 mm (IQR, 2.45–13.8 mm). Twenty lesions (66.6%) were solid, 5 lesions (16.6%) semi-solid, and 5 lesions (16.6%) ground-glass. ICG localization was successful in 28 lesions (93%). Nineteen patients (68%) were intubated only with a double-lumen endotracheal tube (DL-ETT), used for bronchoscopy and surgery, and in 10 patients (36%) ICG marking and surgery were both performed in lateral decubitus. One patient developed a small pneumothorax during bronchoscopy which did not prevent ICG injection. Conclusions: SS-RAB with integrated mCBCT for ICG marking is successful and safe. Single intubation with DL-ETT and lateral decubitus positioning for both bronchoscopy and surgery are feasible. Further studies are needed to prove a potential increase in efficiency with this technique.
- 31 March 2026
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 36 (2)
Chest Wall Disease: An Evolving Surgical Landscape
- 31 March 2026
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 36 (2)
Chest Wall Disease: An Evolving Surgical Landscape
- 24 February 2026
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 36 (2) , 215-222
Physiologic and Functional Outcomes Following Chest Wall Resection
- 24 February 2026
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 36 (2) , 215-222
Physiologic and Functional Outcomes Following Chest Wall Resection
- Open Access
- 5 September 2025
- Published by Elsevier in Lung Cancer
- Vol. 208, 108746
Implications of primary tumor size on overall survival in patients with multifocal T3 non-small cell lung cancer
- 5 September 2025
- Published by Elsevier in Lung Cancer
- Vol. 208, 108746
Open AccessImplications of primary tumor size on overall survival in patients with multifocal T3 non-small cell lung cancer
- 1 August 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (8) , 1244-1253
Race-Specific versus Race-Neutral Pulmonary Function Predicted Values in Patients with Operable Lung Cancer
Rationale: Percent predicted forced expiratory volume in 1 second (FEV1pp) is used for surgical risk assessment in patients with lung cancer. FEV1pp is adjusted for race, despite concerns regarding inaccurate estimations of lung health. Objectives: To compare prediction of race-specific versus race-neutral FEV1pp for pulmonary complications after lung cancer resection. Methods: Patients who underwent lung resection in the Society of Thoracic Surgeons General Thoracic Surgery Database were identified (2002–2008). We used Global Lung Initiative equations to derive race-specific and race-neutral FEV1pp and compared their performance to predict pulmonary complications. Postoperative FEV1pp was calculated with patients categorized into low- (>60%), intermediate- (30–60%), and high- (<30%) risk groups. Results: Of 24,276 patients, most were White (n = 21,130; 87.0%) or Black (n = 1,912; 7.9%). Race-specific equations reduced the mean FEV1pp by 5.3% for White patients and increased it 6.2% for Black patients compared with race-neutral equations. Multivariate models using race-neutral FEV1pp performed similarly to race-specific models in predicting pulmonary complications (sublobar resection: C-statistic 0.72; lobectomy: C-statistic 0.65; and bilobectomy/pneumonectomy: C-statistic 0.67; for both models) with similar adjusted odds ratios of FEV1pp for both equation types. In 5,422 patients with calculable postoperative FEV1pp, 617 (11.4%) were recategorized into a higher (n = 65) or lower (n = 552) risk group when using race-neutral equations. Of those moving into a lower-risk group, 98.0% were White. All patients reclassified into higher-risk groups were Black. Conclusions: Race-neutral FEV1pp performed equally well as race-specific equations in predicting pulmonary complications and disentangled the effect of respiratory function from race on outcomes.
- 1 August 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (8) , 1244-1253
Race-Specific versus Race-Neutral Pulmonary Function Predicted Values in Patients with Operable Lung Cancer
Rationale: Percent predicted forced expiratory volume in 1 second (FEV1pp) is used for surgical risk assessment in patients with lung cancer. FEV1pp is adjusted for race, despite concerns regarding inaccurate estimations of lung health. Objectives: To compare prediction of race-specific versus race-neutral FEV1pp for pulmonary complications after lung cancer resection. Methods: Patients who underwent lung resection in the Society of Thoracic Surgeons General Thoracic Surgery Database were identified (2002–2008). We used Global Lung Initiative equations to derive race-specific and race-neutral FEV1pp and compared their performance to predict pulmonary complications. Postoperative FEV1pp was calculated with patients categorized into low- (>60%), intermediate- (30–60%), and high- (<30%) risk groups. Results: Of 24,276 patients, most were White (n = 21,130; 87.0%) or Black (n = 1,912; 7.9%). Race-specific equations reduced the mean FEV1pp by 5.3% for White patients and increased it 6.2% for Black patients compared with race-neutral equations. Multivariate models using race-neutral FEV1pp performed similarly to race-specific models in predicting pulmonary complications (sublobar resection: C-statistic 0.72; lobectomy: C-statistic 0.65; and bilobectomy/pneumonectomy: C-statistic 0.67; for both models) with similar adjusted odds ratios of FEV1pp for both equation types. In 5,422 patients with calculable postoperative FEV1pp, 617 (11.4%) were recategorized into a higher (n = 65) or lower (n = 552) risk group when using race-neutral equations. Of those moving into a lower-risk group, 98.0% were White. All patients reclassified into higher-risk groups were Black. Conclusions: Race-neutral FEV1pp performed equally well as race-specific equations in predicting pulmonary complications and disentangled the effect of respiratory function from race on outcomes.
- 11 April 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 120 (2) , 401-410
Association of Medicaid Expansion With Timely Treatment and Access to High-Volume Hospitals in Early-Stage Lung Cancer Patients
- 11 April 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 120 (2) , 401-410
Association of Medicaid Expansion With Timely Treatment and Access to High-Volume Hospitals in Early-Stage Lung Cancer Patients
- Open Access
- 1 February 2025
- Published by AME Publishing Company in Current Challenges in Thoracic Surgery
- Vol. 7, 4
Surgical considerations in non-small cell lung cancer patients following neoadjuvant immunotherapy or targeted therapy: a narrative review
Background and Objective: Treatment of early-stage non-small cell lung cancer (NSCLC) is rapidly changing. The addition of immunotherapy and newer targeted therapies to treatment paradigms have demonstrated significant benefit in improving oncologic outcomes. Use of emerging systemic therapies in the neoadjuvant setting introduces novel considerations at the time of surgical resection. In this review, we discuss the current data and ongoing trials involving neoadjuvant chemoimmunotherapy and targeted therapies for early-stage NSCLC. Our objective was to review surgical considerations and outcomes for patients receiving these therapies preoperatively. Methods: A query was made of the MEDLINE (PubMed) database on September 1, 2024 for articles written in English addressing neoadjuvant chemoimmunotherapy and targeted therapies for early-stage NSCLC. Search terms used included “neoadjuvant therapy” or “neoadjuvant chemoimmunotherapy” or “neoadjuvant targeted therapy” combined with “non-small cell lung cancer” and “surgical outcomes” or “surgical complications”. Key Content and Findings: We reviewed major phase II–III studies of neoadjuvant chemoimmunotherapy and targeted therapies for patients with early-stage NSCLC. These trials demonstrated significant improvements in disease-free survival and major or complete pathologic response rates with neoadjuvant immunotherapy when compared to control arms. The available data suggests that surgical resection can be performed safely after immunotherapy without significant increases in postoperative complications. Data regarding surgical outcomes following targeted therapy is limited, particularly for newer generation agents, with several phase II–III trials ongoing. Conclusions: Despite reported increased fibrosis after the receipt of neoadjuvant immunotherapy, the available evidence suggests surgical outcomes were similar to those receiving chemotherapy alone. Ongoing neoadjuvant studies of targeted therapies in NSCLC patients will further inform the safety of resection in these populations.
- 1 February 2025
- Published by AME Publishing Company in Current Challenges in Thoracic Surgery
- Vol. 7, 4
Open AccessSurgical considerations in non-small cell lung cancer patients following neoadjuvant immunotherapy or targeted therapy: a narrative review
Background and Objective: Treatment of early-stage non-small cell lung cancer (NSCLC) is rapidly changing. The addition of immunotherapy and newer targeted therapies to treatment paradigms have demonstrated significant benefit in improving oncologic outcomes. Use of emerging systemic therapies in the neoadjuvant setting introduces novel considerations at the time of surgical resection. In this review, we discuss the current data and ongoing trials involving neoadjuvant chemoimmunotherapy and targeted therapies for early-stage NSCLC. Our objective was to review surgical considerations and outcomes for patients receiving these therapies preoperatively. Methods: A query was made of the MEDLINE (PubMed) database on September 1, 2024 for articles written in English addressing neoadjuvant chemoimmunotherapy and targeted therapies for early-stage NSCLC. Search terms used included “neoadjuvant therapy” or “neoadjuvant chemoimmunotherapy” or “neoadjuvant targeted therapy” combined with “non-small cell lung cancer” and “surgical outcomes” or “surgical complications”. Key Content and Findings: We reviewed major phase II–III studies of neoadjuvant chemoimmunotherapy and targeted therapies for patients with early-stage NSCLC. These trials demonstrated significant improvements in disease-free survival and major or complete pathologic response rates with neoadjuvant immunotherapy when compared to control arms. The available data suggests that surgical resection can be performed safely after immunotherapy without significant increases in postoperative complications. Data regarding surgical outcomes following targeted therapy is limited, particularly for newer generation agents, with several phase II–III trials ongoing. Conclusions: Despite reported increased fibrosis after the receipt of neoadjuvant immunotherapy, the available evidence suggests surgical outcomes were similar to those receiving chemotherapy alone. Ongoing neoadjuvant studies of targeted therapies in NSCLC patients will further inform the safety of resection in these populations.